Keywords
How to Cite
Abstract
Anaplastic large cell lymphoma ALK negative is an entity classified as part of peripheral T-cell neoplasm with CD30 uniform expression. Overall prognosis is usually poor, with a high rate of relapse after first line chemotherapy. Brentuximab vedotin is an antibody–drug conjugate that targets CD30, being an attractive treatment option. Case report: A 65 year old man, with past medical history of chronic obstructive pulmonary disease, presented with progressive nasal occlusion. A biopsy was taken from intranasal mass which revealed ALK negative anaplastic large cell lymphoma. He had multiple extranodal involvement. He received 6 cycles of chemotherapy with vincristine, prednisone, etoposide, cyclophosphamide and doxorubicin. Due to the presence of refractory disease, brentuximab vedotin was given. After three courses, severe pulmonary event appeared, so treatment was suspended but complete remission was obtained. He is now in plan of autologous stem cell transplantation. Discussion: ALK negative anaplastic large cell lymphoma is a disease with an unfortunate prognosis. Brentuximab vedotin has been reported to induce good objective and complete rate responses. Nevertheless, its long time remission is apparently poor, being the stem cell transplantation a considerable option of consolidation treatment in many centers.
References
(Williston Park). 2010;24(June (7)):574–87.
2. Sibon D, Fournier M, Briere J et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d’Étude
des Lymphomes de l’Adulte (GELA). Blood. 2010;116:322.
3. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15.
4. Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97.
5. Younes A1, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812-21.
6. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD. International Peripheral T-Cell
Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496-504.
7. Kewalramani T, Zelenetz AD, Teruya- Feldstein J et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 134:202-207, 2006.
8. Vose JM, Peterson C, Bierman PJ et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin’s lymphomas. Blood. 76:424-
431, 1990.
9. Rodriguez J, Munsell M, Yazji S, et al: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 19:3766-3770, 2001.
10. Moskowitz CH, Nimer SD, Glassman JR et al: The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant. 23:561-567, 1999.
11. Shipp MA, Abeloff MD, Antman KH et al: International Consensus Conference on HighDose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: Report of the jury. J Clin Oncol. 17:423-429, 1999.
12. Chen R, Wang F, Zhang H, Chen B. Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies.
Drug Des Devel Ther. 2015 Apr 21;9:2277-83.
13. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol.
2012;30(18): 2190–2196.
14. Gopal AK, Ramchandren R, O’Connor OA et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568.
15. Gopal AK, Chen R, Smith SE et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–1243.
16 Horwitz SM, Advani RH, Bartlett NL et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100.
17. Ogura M, Tobinai K, Hatake K et al. Phase I/ II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–846.
18 Jacobsen ED, Sharman JP, Oki Y et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood.
2015;125(9): 1394–1402.
19. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one
quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013 Apr;98(4):611-4.
20. Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Gouill SL, Brière J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C, Gaulard P. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica. 2016 Mar;101(3):e103-6.
21. Ansell SM. Brentuximab vedotin. Blood. 2014 Nov 20;124(22):3197-200.
22. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM,Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 Aug 28;124(9):1473-80.
23.Horwitz SM, Peripheral T-cell lymphomas: greater biological understanding is leading novel therapeutic opportunities. Hematology Education: the education program for the annual congress of the European Hematology Association. 2015;9:279-284)
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar